Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 5, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transfers executed by the GlaxoSmithKline Employee Trust ("the GSK Trust") on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991:
- May 2, 2006: Transfer of 392,457 Ordinary Shares.
- May 3, 2006: Transfer of 146,177 Ordinary Shares.
These transactions were advised to the Company on May 5, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred (538,634) against the company's broader employee share plan activity.
- Confirm the specific impact of these transfers on the beneficial ownership of the three named directors.
- Note that this filing contains no financial results; refer to Form 20-F for comprehensive financial data.